Home
Contact
Sitemap
Santen Worldwide
HOME
About Santen
News
Investor Relations
Products
Careers
News Releases
News Releases
2010
2009
2008
2007
2006
2005
2004
2003
2002
2010
Aug 3, 2010
Santen Announces Financial Result for the First Quarter ended June 30, 2010
Jul 6, 2010
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Jun 23, 2010
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Jun 11, 2010
Banyu and Santen Launch COSOPT® Combination Ophthalmic Solution: Glaucoma and Ocular Hypertension Drug
May 11, 2010
Renewal of the Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
May 11, 2010
Notice of the Change of Representative Director and the Nominations for the Members of the Board of Directors
May 11, 2010
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
May 11, 2010
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
May 11, 2010
Santen Announces Financial Results for the Year ended March 31, 2009
May 6, 2010
Santen Launches Glaucoma and Ocular Hypertension Treatment TAFLOTAN® in Korea
May 3, 2010
Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for Development of Ophthalmic Treatments
Apr 16, 2010
MHLW Grants Approval for COSOPT Combination Ophthalmic Solution
Apr 16, 2010
Santen Announces Approval of DIQUAS for Dry Eye Treatment in Japan
Mar 10, 2010
Change of management positions at Santen Inc.
Mar 10, 2010
Notice of the appointment of Corporate Officers
Mar 2, 2010
Banyu and Santen Announce Co-Promotion Agreement for Combination Ophthalmic Solution, Treatment for Glaucoma and Ocular Hypertension
Mar 2, 2010
Santen Files Manufacturing/Marketing Approval of its Broad Spectrum Anti-Infective Ophthalmic Solution DE-108 (Generic name: Levofloxacin, high concentration)
Feb 2, 2010
Santen Announces Financial Result for the Third Quarter ended December 31, 2009
Back to top
Download Adobe® Reader® to view PDF files.